Introduction {#S0001}
============

The success of antiretroviral therapy (ART) roll-out in sub-Saharan Africa has been remarkable. Between 2004 and the end of 2011, around 8 million people had initiated ART, leading to dramatic reductions in HIV-associated morbidity and mortality \[[@CIT0001]--[@CIT0003]\]. However, due to low HIV test uptake and losses along the pathway between HIV testing and ART treatment \[[@CIT0004]\], only a minority of individuals in need of ART are estimated to ever start treatment \[[@CIT0005]\]. This is further compounded by substantial additional losses that occur during long-term treatment \[[@CIT0006],[@CIT0007]\].

The essential steps in the HIV care pathway for HIV-positive individuals are HIV testing, assessment of eligibility for ART, pre-ART care, initiation of ART and long-term retention on ART. The importance of linkage and engagement in care has received considerable attention in high-income countries \[[@CIT0008]--[@CIT0010]\] where successes have resulted in improved health outcomes for the patient \[[@CIT0011],[@CIT0012]\] and reduced costs for the healthcare system \[[@CIT0013]\]. Characterization of losses along the care pathway in high-income countries \[[@CIT0013]--[@CIT0015]\] has informed the development of potential interventions \[[@CIT0009]\]. However, the scale of the challenge is so much greater in sub-Saharan Africa where millions of patients are in need of life-long treatment where healthcare systems are less well developed. It is unclear whether interventions developed in high-income countries will be feasible in this resource-constrained setting.

In the majority of sub-Saharan African countries, large scale ART roll-out commenced in 2004 as treatment became affordable and major donor-funding mechanisms were established \[[@CIT0016]\]. The rapid implementation of vertically driven programmes was successful in providing life-saving treatment for large numbers of patients in need. However, this success was achieved with insufficient attention being given to the establishment of the necessary linkages and integration of HIV care within the broader health system. These are essential for the establishment of an effective continuum of care both before and during ART.

Engagement in HIV care starts when an individual first tests positive for HIV ([Figure 1](#F0001){ref-type="fig"}). This should be followed by assessment for ART eligibility, which requires World Health Organization (WHO) clinical staging and/or CD4 count testing. CD4 count testing is a two-stage process, which requires that a patient\'s blood sample is obtained and sent for processing, followed by the patient returning to receive his or her results (typically 1--2 weeks later). Patients who meet the national criteria for initiation of ART should commence ART without undue delay whereas patients not yet eligible should be retained in pre-ART care and undergo regular CD4 count monitoring until the eligibility threshold is reached. Once patients initiate ART, they should remain on uninterrupted treatment for life. Losses occur at different steps along this pathway, and may be temporary or permanent. The care pathway is not a simple linear process and the dynamic nature of linkage, retention, loss and re-engagement in care, especially in the pre-ART stage, makes this a challenging pathway to assess.

![The care pathway for HIV positive individuals.](JIAS-15-17383-g001){#F0001}

To date, the majority of studies from sub-Saharan Africa have focused on treatment adherence and retention of patients who have started ART \[[@CIT0006],[@CIT0007],[@CIT0017]--[@CIT0020]\]. However, much more needs to be understood about the earlier components of the care pathway. In addition, most studies have reported on rates and risk factors for loss to care, with little focus on potential interventions. In this article, we review the continuum of HIV care from infection to treatment, quantify losses along the pathway in sub-Saharan Africa, and review interventions to decrease attrition at different points in the pathway.

Methods {#S0002}
=======

Definitions {#S0002-S20001}
-----------

For the purpose of this review, we have divided the HIV care pathway into (1) HIV testing; (2) pre-ART care comprising assessment of ART eligibility, retention in pre-ART care prior to ART eligibility, initiation of ART; and (3) retention in ART care ([Figure 1](#F0001){ref-type="fig"}). Where available, we used synthesized data from published systematic reviews or from WHO reports. Where such data were either unavailable or a more comprehensive review was possible, we conducted systematic literature reviews and data syntheses. Possible interventions and operational solutions aimed to reduce losses at each stage of the pathway are subsequently reviewed and discussed.

Eligibility criteria and search strategy {#S0002-S20002}
----------------------------------------

We sought studies investigating retention in care in the pre-ART period, and linkage to care at three steps: ART eligibility assessment, pre-ART care and ART initiation. Studies were omitted if they were carried out in the private healthcare sector, if they reported unsystematic observations (case reports and case series), or if they were secondary data sources (editorials and viewpoints).

Primary outcomes were the proportion of individuals completing ART assessment, retained in pre-ART care and initiating ART as defined by the authors of the study.

We searched Medline, Embase and Global Health for studies reporting retention between HIV testing and ART using a compound search strategy. Bibliographies of retrieved articles were searched for additional studies. Our search was limited to studies conducted in sub-Saharan Africa published between 2000 and June 2011. In addition, we searched for conference abstracts from all conferences of the International AIDS Society (2000--2010), and all Conference on Retroviruses and Opportunistic Infections (2000--2010). No language restriction was applied.

Studies were entered into an electronic database (EndNote X1) to screen potentially eligible studies by title and abstract. Articles were screened by title, then by abstract, independently, and in duplicate (GD, KK). Data was extracted in duplicate (GD, KK) using a standard data extraction form.

Data analysis {#S0002-S20003}
-------------

We calculated point estimates and 95% confidence intervals (CIs) for the proportion of patients linking to care at various stages of the care pathway. The variance of the raw proportions was stabilized using a Freeman-Tukey type arcsine square-root transformation, and estimates were pooled using a DerSimonian-Laird random effects model. Between study heterogeneity was assessed with the τ^2^ statistic (on the transformed scale), and subgroup analyses were run to compare studies that used a time cut-off for determining linkage with those that did not. All *p* values were two-sided, and a *p* value of \<0.05 was considered significant. Analyses were conducted using Stata (version 11, [www.stata.com](http://www.stata.com)).

Results {#S0003}
=======

Out of 755 potentially eligible studies, 37 were retained for analysis ([Figure 2](#F0002){ref-type="fig"}). Study characteristics are summarized according to the different steps in the pathway ([Tables 1](#T0001){ref-type="table"}--[4](#T0004){ref-type="table"}).

![Study selection process.](JIAS-15-17383-g002){#F0002}

###### 

Proportion of patients with newly diagnosed HIV infection who complete assessment of eligibility for antiretroviral therapy

  Author                        Country      Setting                                                          Year of the study   *N*     Enrolled into HIV care as a prerequisite of accessing CD4 counts (time cut-off)   Blood sample for CD4 count provided (time cut-off)   Returned for CD4 results (time cut-off)   Enrolled in HIV care (time cut-off)
  ----------------------------- ------------ ---------------------------------------------------------------- ------------------- ------- --------------------------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------- --------------------------------------------------------------
  Assefa \[[@CIT0021]\]         Ethiopia     Public sector sites                                              2008                1314                                                                                                                                                                                     47% (immediately after testing)
  Assefa \[[@CIT0021]\]         Ethiopia     Mobile HIV testing service for high risk individuals             2008                2035                                                                                                                                                                                     26% (two months)
  Mulissa \[[@CIT0022]\]        Ethiopia     Urban, hospital                                                  2003--08            2191                                                                                                                                                                                     70% (no time cut-off, but 49% enrolled the same day)
  Amolloh \[[@CIT0023]\]        Kenya        Asembo, home-based testing service                               2008--09            737                                                                                                                                                                                      42% (two to four months)
  Waxman \[[@CIT0024]\]         Kenya        Eldoret, emergency department, hospital                          2006                61                                                                                        87% (no time cut-off)                                                                          
  Gareta \[[@CIT0025]\]         Malawi       Lilongwe, hospital, pregnant women                               2006--08            478                                                                                                                                                                                      55% (no time cut-off)
  Tayler Smith \[[@CIT0026]\]   Malawi       Thylo, district hospital, patients with clinical stage I or II   2008--09            1428                                                                                                                                           45% (at least one month follow-up)        
  Micek \[[@CIT0027]\]          Mozambique   Urban, HIV testing services                                      2004--05            7005    57% (30 days)                                                                     77% (30 days)                                                                                  
  Braunstein \[[@CIT0028]\]     Rwanda       Kigali, female sex workers                                       2007--08            141                                                                                                                                                                                      85% (no time cut off)
  April \[[@CIT0029]\]          SA           Cape Town, hospital, primary care clinic                         2006                375                                                                                       62% (six months)                                                                               
  Kranzer \[[@CIT0030]\]        SA           Cape Town, hospital, primary care clinic                         2004--09            988                                                                                       63% (six months)                                                                               
  Larson \[[@CIT0031]\]         SA           Johannesburg, hospital, clinic                                   2008--09            416                                                                                       85% (12 weeks)                                       35% (12 weeks)                            
  Losina \[[@CIT0032]\]         SA           Durban, semi-private hospital                                    2006--07            454                                                                                       55% (eight weeks)                                    85% (eight weeks)                         
  Naidoo \[[@CIT0033]\]         SA           Johannesburg, clinic                                                                 225                                                                                                                                            47% (one week)                            
  Govindasamy \[[@CIT0034]\]    SA           Cape Town, mobile HIV testing service                            2008--09            192                                                                                                                                            73% (no time cut off)                     42% (no time cut off) of those who received their CD4 result
  Bassett \[[@CIT0035]\]        SA           Durban, semi-private hospital                                    2006--08            1474                                                                                      69% (90 days)                                                                                  
  Ingle \[[@CIT0036]\]          SA           Free State, public sector clinics                                2004--07            44844                                                                                     74% (no time cut-off)                                                                          
  Luseno \[[@CIT0037]\]         SA           Community-based trial                                                                199                                                                                                                                                                                      46% (no time cut off)
  Nsigaye \[[@CIT0038]\]        Tanzania     Clinic                                                           2005--08            349                                                                                                                                                                                      68% (no time cut-off)
  Amuron \[[@CIT0039]\]         Uganda       Jinja, clinic                                                    2004--06            2483                                                                                                                                           88% (no time cut-off)                     
  Wanyenze \[[@CIT0040]\]       Uganda       Kampala, hospital                                                2004--05            142                                                                                                                                                                                      56% (six months)
  Nakigozi \[[@CIT0041]\]       Uganda       Rakai community cohort study                                                         1145                                                                                                                                                                                     69% (six months)
  Wanyenze \[[@CIT0042]\]       Uganda       Kampala, hospital                                                2004                211                                                                                                                                                                                      48% (three months), 57% (six months)

###### 

Proportion of individuals with new HIV diagnoses who are eligible for antiretroviral therapy

  Author                      Time       Country      Site                            *N*     CD4\<200                                    CD4\<350   Stage 3   Stage 4   Eligible   Eligibility criteria
  --------------------------- ---------- ------------ ------------------------------- ------- ------------------------------------------- ---------- --------- --------- ---------- -------------------------------------------------------------
  Mulissa \[[@CIT0022]\]      2003--08   Ethiopia     Clinic                          2191                                                           49%       13.3%                
  Mcgrath \[[@CIT0043]\]      2005--06   Malawi       Hospital                        730                                                                                87%        Stage 3 or 4
  Micek \[[@CIT0027]\]        2004--05   Mozambique   Clinic                          3046                                                                               49%        CD4\<200 or stage 4, CD4 200 to 350 or stage 3 and pregnant
  Nakanjako \[[@CIT0044]\]    2004       Nigeria      Emergency department            111                                                            49%       22.0%                
  Braunstein \[[@CIT0028]\]   2006--07   Rwanda       FSW                             192     11%                                         43%                                       
  Kranzer \[[@CIT0030]\]      2004--09   SA           Primary care clinic, hospital   112     34%                                         60%                                       
  van Schaik \[[@CIT0045]\]   2008--09   SA           Mobile clinic                   65      11%                                         25%                                       
  Basset \[[@CIT0035]\]       2006--08   SA           Semi-private hospital           1012    53%                                                                                   
  Ingle \[[@CIT0036]\]        2004--07   SA           Public clinics, hospitals       33182   57% (04)[a](#TF0001){ref-type="table-fn"}                                             
                                                                                              54% (05/6)                                                                            
                                                                                              67% (07)                                                                              
  Lessels \[[@CIT0046]\]      2007       SA           Clinic                          7655    41%                                         62%                                       
  Losina \[[@CIT0032]\]       2006--07   SA           Semi-private hospital           248     53%                                                                                   
  April \[[@CIT0029]\]        2006       SA           Primary care clinic, hospital   375     31%                                                    31%                            
  Nunu \[[@CIT0047]\]         2009       Swaziland    Hospital                        637                                                                                57%        Not stated
  Konde-Lule \[[@CIT0048]\]              Uganda       Public clinics, hospitals       203     36%                                         57%                                       
  Amuron \[[@CIT0039]\]       2004--06   Uganda       Clinic                          4321                                                                               58%        CD4\<200 or WHO Stage 4
  Carter \[[@CIT0049]\]       2003--08   Multisite    ANC, post pregnancy             6036    21%                                         45%        10%       1%                   

Proportions were calculated on the basis of calendar years

###### 

Retention in care of individuals not yet eligible for antiretroviral therapy

  Author                    Country   Setting                                      Year of the study   *N*     Retention in pre-ART care (time cut off)                                                                           Assessment of pre-ART retention   Comment
  ------------------------- --------- -------------------------------------------- ------------------- ------- ------------------------------------------------------------------------------------------------------------------ --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lessells \[[@CIT0046]\]   SA        Rural Kwazulu Natal, public sector clinics   2007                4223    45% (13 months)                                                                                                    repeat CD4 count                  
  Ingle \[[@CIT0036]\]      SA        Free State, public sector clinics            2004--07            11039   42% (six months)                                                                                                   Visits                            12% died, 46% loss to follow-up
  Larson \[[@CIT0050]\]     SA        Johannesburg, hospital, clinic               2007--08            356     CD4 200 to 350: 6% within four months, 41% within one year CD4 350+: 15% within nine months, 26% within one year                                     
  Kranzer \[[@CIT0030]\]    SA        Cape Town, hospital, primary care clinic     2004--09            419\*   46% (no time cut-off)                                                                                              Repeat CD4 count                  
  McGuire \[[@CIT0051]\]    Malawi    Rural Malawi, district hospital, clinics     2004--07            5685    59% (no time cut-off)                                                                                                                                3% known dead, 6% transferred out, 31% loss to follow-up (a sample of the patients lost to follow-up were traced: 26% were alive, 35% were dead, 10% moved, 29% were not found)

###### 

Proportions of HIV-positive individuals assessed as eligible for antiretroviral therapy who start treatment

  Author                        Country      Setting                                                                        Year of the study   *N*     Linkage to ART care for those eligible (time cut-off)   Median (mean) time to ART initiation   Comment
  ----------------------------- ------------ ------------------------------------------------------------------------------ ------------------- ------- ------------------------------------------------------- -------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Karcher \[[@CIT0017]\]        Kenya        Nyanza, district hospital                                                      2004--05            159     78% (no time cut-off)                                                                          3% died, 13% denied treatment
  Tayler-Smith \[[@CIT0052]\]   Kenya        Kibera slum, clinics                                                           2005--08            2471    82% (one month)                                                                                
  Tayler-Smith \[[@CIT0026]\]   Malawi       Thyolo, district hospital, patients with WHO Stage 1/2 and CD4\<250 cells/µL   2008--09            681     64% (six months)                                        33 days (21--44)                       
  Gareta \[[@CIT0025]\]         Malawi       Lilongwe, hospital, pregnant women                                             2006--08            222     69% (four weeks)                                                                               
  Zachariah \[[@CIT0053]\]      Malawi       Thyolo, district hospital, TB patients                                         2003--04            742     14% (no time cut-off)                                                                          
  Mcgrath \[[@CIT0043]\]        Malawi       Karonga rural, district hospital                                               2005--06            659     86% (no time cut-off)                                   22 days (13--27)                       5% died, 0.5% had moved, 3% alive not taking ART, 5% untraceable
  Micek \[[@CIT0027]\]          Mozambique   Urban, HIV testing services                                                    2004--05            1506    31% (90 days)                                           71 days                                
  Kranzer \[[@CIT0030]\]        SA           Cape Town, hospital, primary care clinic                                       2004--09            219\*   67% (within six months)                                                                        
  Ingle \[[@CIT0036]\]          SA           Free State, public sector clinics, eligible at first CD4 measurement           2004--07            19089   59% (no time cut-off)                                   95 days (53--170)                      25% died, 3% in care, 13% not in care
  Ingle \[[@CIT0036]\]          SA           Free State, public sector clinics, eligible at subsequent CD4 measurement      2004--07            2994    58% (no time cut-off)                                                                          13% died, 19% in care, 9% not in care
  April \[[@CIT0029]\]          SA           Cape Town, hospital, primary care clinic                                       2006                72      68% (no time cut-off)                                                                          
  Bassett \[[@CIT0054]\]        SA           Durban, semi-private hospital                                                  2006                501     81% (three months)                                                                             6% died, 3% accessed a different service, 0.6% moved away, 0.6% promised to return, 7% were untraceable
  Bassett \[[@CIT0035]\]        SA           Durban, semi-private hospital                                                  2006--08            538     39% (12 months)                                         6.6 months                             17% died
  Kaplan \[[@CIT0055]\]         SA           Cape Town, primary care clinic, women                                          2002--07            2131    81% (no time cut-off)                                                                          4% died, 7% loss to follow-up
  Lawn \[[@CIT0056]\]           SA           Cape Town, primary care clinic                                                 2002--05            1235    75% (no time cut-off)                                   34 days (28--50)                       5% died, 9% preparing for ART, 11% loss to follow-up
  Feucht \[[@CIT0057]\]         SA           Pretoria, hospital, children                                                   2004                243     40% (no time cut-off)                                                                          
  Geng \[[@CIT0058]\]           SA           Mbarara, clinic                                                                2009--10            697     58% (three months)                                                                             
  Nunu \[[@CIT0047]\]           Swaziland    Hospital                                                                       2009                363     58% (on the assigned date)                                                                     
  Amuron \[[@CIT0039]\]         Uganda       Jinja, clinic                                                                  2004--06            2182    85% (no time cut-off)                                   33 days (15--406)                      Survival status was investigated for all losses between testing and treatment (included losses of patients not returning for their CD4 result): 7% died, 8% on ART with a different provider, 6% were alive and not on ART, 4% untraceable
  Parkes \[[@CIT0059]\]         Uganda       NGOs and governmental health units                                             2004--06            458     61% (three months)                                                                             

HIV testing {#S0003-S20001}
-----------

The proportion of HIV-positive individuals in sub-Saharan Africa whose infection remains undiagnosed is often derived from population-based surveys in which participants are asked to provide details about previous HIV testing. However, a considerable proportion of those who report a previous negative test may have since seroconverted. Thus, the overall median estimate of 39% of people living with HIV in sub-Saharan Africa knowing their correct HIV status may be an overestimate \[[@CIT0005]\]. This is suggested by some country-level studies. For example, the Kenya AIDS Indicator Survey linked HIV test results to perceived HIV status \[[@CIT0060]\]. This revealed that among HIV-positive individuals, 56% reported they did not know their status, 28% mistakenly thought they were HIV-negative and only 16% actually knew their HIV-positive status \[[@CIT0060]\]. Similarly, in a peri-urban South African community with high HIV prevalence, the prevalence of previously undiagnosed HIV was 46% despite coverage of HIV testing being high (71%) \[[@CIT0061]\].

Pre-ART care {#S0003-S20002}
------------

### Assessment of ART eligibility

For individuals who test positive for HIV infection, the next key step in the care pathway is assessment of ART eligibility - a process that might be regarded as indicative of an initial link to care. Of the 22 published studies we identified as eligible for inclusion ([Table 1](#T0001){ref-type="table"}), the majority were conducted in South Africa (*n*=9). Eleven studies reported the proportions of patients enrolling in care post-diagnosis. Two studies were excluded because they were unrepresentative of the general population accessing clinics and hospitals: one was conducted in a mobile clinic \[[@CIT0034]\] and among female sex workers in Rwanda \[[@CIT0028]\].

The proportion of patients assessed for ART eligibility (reflecting linkage to care) ranged from 42% (95% CI, 39% to 46%) to 70% (95% CI, 68% to 72%), with an overall pooled estimate of 57% (95% CI, 48% to 66%; τ^2^ 0.07). In eight out of the eleven studies, ART eligibility was assessed by CD4 cell count measurement and the proportions of patients in which this was successfully performed ranged from 55% (95% CI, 51% to 60%) to 86% (95% CI, 77% to 94%) with a pooled proportion of 66% (95% CI, 54% to 78%; τ^2^ 0.14). However, only five of these studies reported the number of patients who returned for their test result, with proportions ranging from 30% (95% CI, 26% to 34%) to 88% (95% CI, 87% to 89%) and a pooled estimate of 51% (95% CI, 25% to 78%; τ^2^ 0.40). This pooled estimate is similar to the finding of an earlier systematic review in which a median proportion of 59% completed ART eligibility assessment \[[@CIT0004]\].

### Proportion of individuals eligible for ART

We next assessed the proportion of individuals with newly diagnosed HIV infection who were assessed and found to be eligible for ART according to national ART guidelines currently in use at the time of the study. We identified 16 studies eligible for inclusion ([Table 2](#T0002){ref-type="table"}) of which seven were from South Africa. Ten studies reported on the proportions of patients who were eligible for ART based on a CD4 count threshold of ≤200 cells/µL, but two were excluded for reasons of non-generalizability \[[@CIT0028],[@CIT0045]\]. The proportion found to be eligible at this CD4 count threshold ranged from 21% (95% CI, 20% to 22%) to 59% (95% CI, 59% to 60%) with a pooled proportion of 41% (95% CI, 27% to 55%; τ^2^ 0.15). Six studies also reported on the proportions eligible using a CD4 count threshold of ≤350 cells/µL, with proportions ranging from 45% (95% CI, 44% to 47%) to 62% (95% CI, 61% to 63%) and a pooled estimate of 57% (95% CI, 50% to 63; τ^2^ 0.13). Six studies reported on the proportions of patients who were eligible for ART based on clinical criteria (WHO clinical Stage 3 and 4). Proportions ranged from 49% (95% CI, 48% to 51%) to 87% (95% CI, 84% to 89%) with a pooled proportion of 64% (95% CI, 53% to 74%; τ^2^ 0.13).

### Pre-ART care prior to ART eligibility

We identified only five studies reporting on retention in care of individuals not yet eligible for ART; four of these were from South Africa ([Table 3](#T0003){ref-type="table"}). The duration of pre-ART care assessed was highly variable between these studies \[[@CIT0030],[@CIT0036],[@CIT0046],[@CIT0050]\]. No study reported the proportion retained in care on becoming eligible for ART. Retention in pre-ART care in South Africa ranged from 41% to 46% \[[@CIT0030],[@CIT0036],[@CIT0046],[@CIT0050]\]. The remaining study from Malawi estimated retention in pre-ART care to be 59% \[[@CIT0051]\]. The median proportion retained in pre-ART care was 45%. As few studies were identified, all with considerable heterogeneity regarding time-cut offs, a pooled estimate was not calculated. Two of the five studies did not specify any time-cut off \[[@CIT0030],[@CIT0051]\], while the other three studies assessed repeat CD4 count measurements or visits --- six to twelve months after the initial eligibility assessment \[[@CIT0036],[@CIT0046],[@CIT0050]\].

### Initiation of ART

We identified 19 studies that reported the proportions of ART-eligible individuals who started ART ("linkage to ART") ([Table 4](#T0004){ref-type="table"}). Ten studies in seven sites were conducted in South Africa with the remainder conducted in Kenya (*n*=1), Malawi (*n*=4), Mozambique (*n*=1), Swaziland (*n*=1) and Uganda (*n*=2). A study reporting linkage amongst TB, co-infected patients was excluded from the meta-analysis as these patients have an unrepresentative high mortality risk \[[@CIT0053]\]. In the remaining 18 studies, the proportion linking to ART ranged from 31% (95% CI, 29% to 33%) to 86% (95% CI, 83% to 89%), with an overall pooled proportion of 66% (95% CI, 58% to 73%; τ^2^ 0.12). An earlier review of 14 studies found the median proportion of individuals initiating ART was 68% \[[@CIT0004]\]. Eight of the studies included in our meta-analysis did not specify the time period within which patients could link to ART care. However, in a subgroup analysis there was no difference in the proportion linking to ART care comparing studies that used a time cut-off for determining a link with those that did not (*p*=0.24). Studies which reported on time between HIV testing or staging and initiation of ART showed that the majority of patients started treatment within one month; however, two studies reported median delays of between 2.4 and 6.6 months \[[@CIT0027],[@CIT0035]\].

Eight studies assessed the contribution of mortality as a potential cause for not starting ART and reported a median mortality of 5.5% (interquartile range=4.5% to 12%) among eligible patients waiting to start treatment \[[@CIT0017],[@CIT0035],[@CIT0036],[@CIT0039],[@CIT0043],[@CIT0054],[@CIT0056]\]. In these studies, it is difficult to ascertain whether death is the cause or the result of not starting ART. Some studies traced individuals who were thought to have not started ART \[[@CIT0039],[@CIT0054]\]; between 3% and 19% of such patients were either retained in care in the same clinical service or had accessed treatment elsewhere.

ART care {#S0003-S20003}
--------

Patients receiving ART may leave clinical care for three reasons: death, transfer of care to another service (transfer-out) and loss to follow-up. Losses during ART are much better documented than those occurring earlier in the care pathway. Early mortality is typically high in programmes in sub-Saharan Africa \[[@CIT0062]\]. Systematic reviews have estimated that death accounted for around 40% of patient attrition during the first two to three years of treatment \[[@CIT0006],[@CIT0007]\]. Key risk factors for this include a low baseline CD4 count and advanced WHO stage of disease \[[@CIT0063]\]. Thus, interventions upstream in the care pathway are needed to prevent late presentation. Long-term mortality risk decreases substantially \[[@CIT0063]--[@CIT0066]\], especially once a CD4 cell count threshold of 200 cells/µL has been exceeded \[[@CIT0067]\].

Early in the scale-up of ART in sub-Saharan Africa, treatment sites were few; patients were typically severely immunocompromised at the time of ART initiation; and prognosis was uncertain. Thus, transfer of patient care between ART clinics was relatively uncommon. However, over time the number of decentralized treatment sites has expanded; patients are generally less immunocompromised when commencing ART; and patient confidence in ART has grown \[[@CIT0065]\]. These factors may explain why in some settings, rates of transfer between services have risen steeply \[[@CIT0064],[@CIT0068]\]. Data on true outcomes of patients transferred from one program to another are scarce \[[@CIT0069],[@CIT0070]\], but if transfer of care is successful, then the patient is effectively retained in care.

A challenge to rapidly expanding ART programmes in sub-Saharan Africa is the issue of preventing "losses to follow-up." Patients are usually classified as "lost to follow-up" if they fail to attend follow-up appointments over a specified duration without having been actively transferred to another ART clinic, and if they are not known to have died. A systematic review of 39 ART cohorts in sub-Saharan Africa reported an average retention of 65% at three years \[[@CIT0006]\]. In recent years, many ART cohorts have rapidly increased in size with disproportionate increases in the number of patients compared to the number of healthcare workers. Losses to follow-up have reportedly grown over successive calendar periods, indicating a growing problem with long-term retention in care \[[@CIT0064],[@CIT0065],[@CIT0071]\].

Defining a patient as "lost to follow-up" is often based on exclusion of other known reasons for failure of the patient to attend. However, this may conceal considerable unascertained mortality. A systematic review summarizing studies that traced individuals lost to follow-up showed that on average 40% of such individuals had actually died \[[@CIT0072]\]. A study from South Africa reported that 78% of such deaths occurred within the first three months after their last clinic visit \[[@CIT0071]\], suggesting these deaths were the reason and not the result of being lost to follow-up.

Another complexity in reporting rates of loss to follow-up is that patients may cycle in and out of care. Thus, patients who fulfil the widely used definition of loss to follow-up at one time point might re-engage with care at a later stage and thus cease to be lost to follow-up. A systematic review of this issue conducted in 2011 identified nine studies from sub-Saharan Africa and found that an average of 12% of individuals on ART had previously interrupted but subsequently restarted treatment \[[@CIT0073]\].

Cumulative losses along the pathway {#S0003-S20004}
-----------------------------------

No study has yet measured the cumulative losses occurring along the entire care pathway. This would require long-term prospective demographic surveillance, although such a process in itself would likely alter the outcomes of interest. An alternative approach is to combine pooled estimates of losses from each of the steps in the care pathway that we have described. However, using data in this way from cross-sectional studies with typically short duration of follow-up is methodologically flawed \[[@CIT0004]\]. A critical issue is that the care pathway is not a simple linear process and patients clearly cycle in and out of care; a patient who fails to complete one step in the pathway may re-engage with the treatment pathway at a later time-point and ultimately receive successful long-term ART. Thus, use of the individual estimates of the losses described thus far and summarized in [Figure 3](#F0003){ref-type="fig"} might erroneously lead to the conclusion that of all HIV-positive individuals in the community, only 7% (0.39×0.57×0.50×0.66) would start ART and 5% (0.039×0.57×0.50×0.45) would be retained in pre-ART care for some duration.

![Cumulative losses along the HIV care pathway as reported by cross-sectional studies addressing each step in the pathway. The proportions (%) shown indicate the proportions of individuals who successfully complete each step in the pathway.](JIAS-15-17383-g003){#F0003}

The assertion that these are likely to be underestimates of the true proportions receiving care is supported by detailed data from a high HIV prevalence community in South Africa. In a population-based sero-prevalence survey, 54% of all HIV-positive individuals knew their positive HIV sero-status \[[@CIT0061]\]. A study of this community from the same period showed that 63% of HIV-positive individuals were assessed for ART eligibility within six months of diagnosis, 26% were eligible for ART and 66% started ART within six months of diagnosis \[[@CIT0030]\]. Combining these estimates of losses along the HIV care pathway in this community would lead to an estimated ART coverage in the community of 6% (0.54×0.63×0.26×0.66), whereas in reality a population-based survey reported a coverage of 33.5%, which is more than five-fold higher \[[@CIT0061]\]. This illustrates the complexities involved in studying the HIV care pathway and the need for better means of assessment.

Interventions {#S0003-S20005}
-------------

Multiple interventions are needed to address high rates of patient attrition at every stage of the HIV care pathway. Strategies to reduce deaths among patients who have started ART have been described elsewhere \[[@CIT0074]\], so instead, we should focus on strategies to increase HIV diagnosis and engagement of patients in pre-ART care and aim to reduce losses to follow-up throughout the pathway.

Interventions either aim to increase the efficiency and capacity of services, or accessibility and acceptability of these services ([Table 5](#T0005){ref-type="table"}). Interventions to increase HIV testing include task-shifting (testing through lay healthcare workers) \[[@CIT0077]--[@CIT0079]\] and provider-initiated testing \[[@CIT0089]--[@CIT0091]\] as well as mobile, community, home-based and workplace services [@CIT0083]--[@CIT0087],[@CIT0092]\] which bring the service nearer to the patient and thus increase accessibility, which might in turn increase acceptability. Other interventions aimed to increase acceptability of testing are self-testing \[[@CIT0080]\] and incentivized testing \[[@CIT0093],[@CIT0094]\]. More recently, community-based strategies for HIV testing and ART delivery have been developed \[[@CIT0084],[@CIT0088],[@CIT0099]\] as a way to further expand access to care. By virtue of being placed in the community, these strategies are decentralized and use task-shifting to engage lesser trained health staff, and thus might be more cost-effective \[[@CIT0125]\].

###### 

Interventions to increase HIV diagnosis and engagement of patients in pre-ART HIV care and to reduce losses to follow-up throughout the care pathway

  Step           Targeting                                                   Intervention/operational solution                                                                                                                                                                                                                                                                Evidence
  -------------- ----------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                 HIV testing capacity                                        Integration of HIV testing into other healthcare servicesTesting by lay healthcare workersDecentralization of testingSelf-testing                                                                                                                                                                Observational studies \[[@CIT0075],[@CIT0076]\]Observational studies \[[@CIT0077]--[@CIT0079]\]Feasibility study \[[@CIT0080]\]
  HIV testing    Demand for HIV testing                                      Targeted testing in high risk groupsHome-based and community-based testing, mobile servicesProvider-initiated testingWorkplace testingIncentivized testingSelf-testing                                                                                                                           Observational studies \[[@CIT0081],[@CIT0082]\]RCT \[[@CIT0083]\], observational studies \[[@CIT0084]--[@CIT0087],[@CIT0093]\]Observational studies \[[@CIT0089]--[@CIT0091]\]RCT \[[@CIT0087]\]RCT \[[@CIT0093],[@CIT0094]\]Feasibility study \[[@CIT0080]\]
                 Completion of staging and linkage to pre-ART and ART care   Point of Care CD4 count testingDecentralizationIntegration into existing services/primary healthcareSupport tools (e.g. cell phone messages, patient held appointment cards)                                                                                                                     Observational studies \[[@CIT0095],[@CIT0096]\]Observational study \[[@CIT0038]\]Observational study \[[@CIT0038]\]
                                                                                                                                                                                                                                                                                                                                                                              
  Pre-ART care   Retention in pre-ART care prior to ART eligibility          Efficient referral serviceTransport allowanceAdherence counsellingRegular visits (e.g. Cotrimoxazole prophylaxis)DecentralizationIntegration into existing services/primary healthcareTask shiftingEarlier initiation                                                                            Observational study \[[@CIT0097]\]
                                                                             Home-delivered ARTCommunity ARTTargeted adherence counsellingDrugs with less toxicity, side effects and easier scheduleTask shiftingDecentralization                                                                                                                                             RCT \[[@CIT0098]\]Observational study \[[@CIT0099],[@CIT0100]\]Observational studies \[[@CIT0101],[@CIT0102]\]Some evidence from resource rich settings[@CIT0103]RCT[@CIT0104], observational studies \[[@CIT0102],[@CIT0105]--[@CIT0109]\]Observational study \[[@CIT0077],[@CIT0106],[@CIT0108]--[@CIT0113]\]
  ART care       Increase retention                                          Integration into existing services/primary healthcareSupport tools (cell phones, lay community adherence counsellors)Continuous drug supplyTransport re-imbursementEarly initiationImproved referral systems                                                                                     Feasibility study \[[@CIT0114]\], RCT for PMTCT \[[@CIT0115]\]RCT \[[@CIT0116]\], observational studies \[[@CIT0117]\]Observational studies \[[@CIT0118],[@CIT0119]\]Qualitative studies \[[@CIT0118],[@CIT0120],[@CIT0121]\]Observational study \[[@CIT0122]\]
                 Increase re-initiation for treatment interrupters           Incentives such as nutritional supportHealth information systems to allow patients to be tracked between servicesTracing of individuals loss to follow-up (home visits, cell phones)Health information systems to allow patients to be tracked between servicesPatient and community education   Observational studies \[[@CIT0123],[@CIT0124]\]

Only four studies have assessed interventions aimed at reducing losses in the pre-ART period. These have examined point-of-care CD4 count testing \[[@CIT0095],[@CIT0096]\], more efficient referral systems \[[@CIT0038]\], transport vouchers \[[@CIT0038]\] and regular visits to refill trimethoprim-sulphmethoxazole prophylaxis \[[@CIT0097]\]. In contrast, many studies have reported on interventions to reduce loss to follow-up of patients on ART \[[@CIT0126]\]. Some of these interventions are structural such as task-shifting \[[@CIT0104]--[@CIT0108]\], decentralization \[[@CIT0077],[@CIT0106],[@CIT0108]--[@CIT0111]\], integration \[[@CIT0114],[@CIT0115]\] and continuous drug supply \[[@CIT0118],[@CIT0119]\], whereas others are aimed at the individual such as adherence counselling \[[@CIT0101],[@CIT0102]\] and transport reimbursement \[[@CIT0118],[@CIT0120],[@CIT0121]\].

Few interventions have been assessed for their efficacy and cost-effectiveness in randomized controlled trials \[[@CIT0083],[@CIT0092],[@CIT0094],[@CIT0104],[@CIT0116]\], and most observational studies have assessed feasibility rather than effectiveness \[[@CIT0080],[@CIT0114],[@CIT0123]\]. Evidence for a positive effect of, for example, transport vouchers and secured drug supplies comes mainly from risk factor analysis and semi-qualitative studies \[[@CIT0118]--[@CIT0121]\]. Some interventions have only been assessed for one specific step in the pathway, but not for others. An example is adherence counselling, which has been shown to have some effect on retention in ART care \[[@CIT0101],[@CIT0102]\], but the effect of counselling on retention in pre-ART care or on linkage to ART care has not yet been formally assessed.

Integration of care has mainly concentrated on tuberculosis and PMTCT programs \[[@CIT0115],[@CIT0127]\] or the beneficial effects derived by other health services through the integration of HIV care \[[@CIT0128]\]. The lack of a common conceptual framework on what integration means has impeded more rigorous evaluation of the impact of integration on retention and testing \[[@CIT0129]\]. One study conducted in nine countries in sub-Saharan Africa, found that providing ART in an integrated approach resulted in substantially less defaulting from care compared to vertical ART delivery \[[@CIT0130]\]. As HIV is a chronic disease, integration is important not only to improve retention, but also to provide comprehensive care ([Table 6](#T0006){ref-type="table"}). This has been conceptualized in the WHO\'s Integrated Management of Adolescent and Adult Illness programme \[[@CIT0131]\].

###### 

Comprehensive HIV care

  -------------------------------------------------------------------
  Prevention
   Trimethoprim-sulphamethoxazole prophylaxis
   Isoniazid preventive therapy
   Intensified tuberculosis case finding
   Cryptococcal antigen screening
   Cervical cancer screening
   Prevention of mother to child transmission
   Prevention of transmission to sexual partners
  Acute services
   Tuberculosis
   Mental health
   Sexual transmitted diseases
   Antenatal care
   Family planning
  Chronic services
   Mental health
   Chronic disease (e.g. diabetes, ophthalmological services, etc.)
   Care of the elderly services
   Social support
  -------------------------------------------------------------------

Conclusions {#S0004}
===========

Substantial losses occur at every stage of the HIV care pathway for HIV-positive individuals in sub-Saharan Africa. Assessment of these losses is complex as is engagement in care; loss to care and return to care is a dynamic, non-linear and time-dependent process. To date, no study has yet defined the cumulative losses throughout the pathway. Data regarding interventions to address these losses are scarce, especially with regards to the care pathway prior to ART initiation. Research is urgently needed to identify effective solutions so that a far greater proportion of HIV-positive individuals can reap the benefits of ART. Such research should take into account the important gender differences that are becoming increasingly apparent with respect to accessing testing \[[@CIT0132]\] and treatment and care \[[@CIT0133]\].

The "test and treat" approach to reducing HIV transmission proposes that very high coverage of HIV testing and immediate initiation of ART regardless of the stage of HIV progression would substantially reduce HIV transmission \[[@CIT0134]\], and has been met with considerable enthusiasm. The data in this review serve as a reminder of the huge operational challenges that will be faced in implementing such a strategy. Considerable investment and energy must be devoted to identifying effective interventions to strengthen the care pathway, thereby permitting more effective implementation of current policy. As the care pathway is strengthened, "test and treat" will become a more viable strategy.
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